Bristol-Myers Squibb Rating Reiterated by William Blair (BMY)
Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a report issued on Thursday, Stock Ratings Network.com reports.
Bristol-Myers Squibb (NYSE:BMY) opened at 52.12 on Thursday. Bristol-Myers Squibb has a one year low of $41.11 and a one year high of $57.49. The stock’s 50-day moving average is $50.52 and its 200-day moving average is $52.20. The company has a market cap of $86.372 billion and a price-to-earnings ratio of 30.17.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Tuesday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.03. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.89 billion. During the same quarter in the previous year, the company posted $0.41 earnings per share. The company’s revenue for the quarter was down .5% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post $1.79 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on BMY. Analysts at BMO Capital Markets downgraded shares of Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research note on Thursday. They now have a $55.00 price target on the stock, down previously from $60.00. Separately, analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb to $50.00 in a research note on Wednesday, May 7th. They now have a “hold” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, April 30th. They now have a $52.00 price target on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Buy” and an average target price of $56.15.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.